The Science of Slowing Aging How Existing Drugs Could Extend Human Lifespan

The Quest to Slow Aging

For decades, the idea of extending human lifespan was relegated to science fiction and fringe biology. Today, it sits at the center of serious scientific inquiry, backed by major universities, billion-dollar investment funds, and an expanding body of peer-reviewed research. The latest breakthrough comes not from inventing a new molecule, but from looking at old ones in a completely new way.

A landmark study published in Nature Aging by researchers at Northeastern University and Harvard has introduced a powerful computational method for predicting which existing, FDA-approved drugs might also slow the biological processes of aging. The approach could dramatically accelerate the timeline from laboratory discovery to clinical application, potentially shaving years off the drug development process for longevity therapeutics.

Network Medicine Meets Geroscience

The study, led by postdoctoral researcher Bnaya Gross in the lab of physicist Albert-László Barabási, applies a framework called network medicine to the biology of aging. Network medicine treats proteins not as isolated actors but as nodes in a vast, interconnected web of physical and functional interactions known as the interactome. The human interactome comprises more than 500,000 experimentally verified protein-protein interactions.

The core insight is elegant: just as genes underlying a specific disease tend to cluster together into a “disease module” within the interactome, the genes associated with each hallmark of aging — cellular senescence, mitochondrial dysfunction, genomic instability, telomere attrition, and others — form their own distinct neighborhoods. By measuring how close a drug’s protein targets sit to these aging-related neighborhoods, researchers can predict whether that drug is likely to perturb the aging process.

“You have genes related to aging by some definition or by some reasoning, but it feels like you just have a very big pile of genes related to aging,” Gross explained. “Networks allow us to organize them, saying, OK, it’s not just a pile of genes. They are connected to each other. They form some sort of organization. It’s not a random process.”

From 2,358 Genes to 370 Drug Candidates

The research team began with the OpenGenes database, a manually curated resource that links 2,358 genes to aging and longevity. Each gene carries a confidence score from 1 to 5, where level 1 means that altering the gene’s activity has been shown to extend mammalian lifespan. Strikingly, only 26 genes meet this highest confidence threshold, underscoring how much remains unknown about the genetic architecture of longevity.

Of the 2,358 genes, 1,250 could be confidently assigned to at least one hallmark of aging. The remaining 1,108 are clearly aging-related but could not yet be pinned to a specific hallmark. Notably, 390 genes belong to multiple hallmarks, with the tumor suppressor gene TP53 spanning seven — a testament to how deeply intertwined the aging processes truly are.

The team then screened 6,442 compounds from DrugBank against each hallmark module. They measured network proximity — the average shortest-path distance from a drug’s protein targets to the nearest aging-related genes. Drugs whose targets sit significantly closer than random chance predicted were flagged as candidates for perturbing that hallmark.

The result: 370 existing drugs were identified as proximal to at least one hallmark of aging. Even more intriguing, 83 of these are network drugs — compounds that do not directly target any known aging gene but influence the aging network indirectly through protein interactions. These hidden candidates would be completely invisible to any conventional approach that only examines direct drug-target relationships.

The pAGE Metric and the SHARP Pipeline

One critical challenge the researchers faced was directionality. Network proximity tells you that a drug acts on a hallmark, but not whether it helps or harms. Some drugs identified by proximity actually induced cellular senescence rather than reducing it — the opposite of what a longevity therapeutic should do.

To solve this, the team developed a new metric called pAGE that accounts for whether a drug’s effect is beneficial or detrimental to each hallmark. They combined proximity and pAGE into a systematic pipeline called SHARP — the Systematic Hallmark-based Aging Repurposing Pipeline.

Validation of SHARP was rigorous. The team tested it against compounds from the National Institute on Aging’s Intervention Testing Program (ITP), a multi-institutional effort to screen drugs for lifespan extension in mice. Of the eight ITP compounds that successfully increased mouse lifespan and had interactomic data available, all showed a positive pAGE for at least one hallmark. Of the drugs that failed in ITP trials, fewer than half showed a positive pAGE — a meaningful signal that the metric tracks real biological relevance.

Surprising Findings and Trade-Offs

The study produced several surprising findings that challenge conventional assumptions in geroscience:

• Rapamycin hits only one hallmark — Despite being one of the most celebrated longevity drugs, rapamycin mapped to just a single hallmark (intercellular communication) in the network analysis. This suggests its benefits may be more targeted than previously assumed.
• Aspirin is broad-spectrum — The common pain reliever mapped to six different hallmarks of aging, suggesting a surprisingly wide-ranging effect on aging biology.
• Dasatinib hits five hallmarks — This cancer drug, already being studied in senolytic combinations, showed broad network proximity across multiple aging processes.
• Trade-offs are real — Several pro-longevity drugs were found to be beneficial for some hallmarks but harmful for others, highlighting the complexity of pharmacological aging interventions and the need for combinatorial strategies.

The researchers also successfully tested SHARP against 10 compounds from a parallel study whose results were published after their predictions were made — the closest thing to a prospective validation. This forward-looking accuracy lends significant credibility to the approach.

Why Drug Repurposing Matters for Longevity

The traditional drug development pipeline takes 10 to 15 years and costs billions of dollars per approved compound. For aging — a condition that is not classified as a disease by most regulatory frameworks — the barriers are even higher. The FDA does not recognize aging as an indication, which means any drug targeting aging must be approved for a specific age-related disease first.

Drug repurposing sidesteps much of this problem. Existing drugs have already passed safety testing, have established dosing protocols, and have known side-effect profiles. If a compound already approved for diabetes, hypertension, or cancer also happens to slow one or more hallmarks of aging, the path to clinical use in a longevity context could be dramatically shorter.

This is precisely what the SHARP pipeline aims to accelerate. By computationally screening thousands of known drugs against the biological architecture of aging, researchers can prioritize the most promising candidates for expensive, time-consuming animal and human trials.

The Broader Longevity Landscape

The network medicine study is part of a broader surge in longevity science. Several concurrent developments are reshaping the field:

Epigenetic Clocks

Directly measuring the effect of a drug on human aging would take decades, which is why scientists rely on proxy markers. Epigenetic clocks — biochemical tests that measure DNA methylation patterns to estimate biological age — have become indispensable tools. These clocks allow researchers to assess whether an intervention is actually slowing the aging process within months rather than waiting decades for mortality outcomes.

The 194-Year Question

Recent research has suggested that the upper limit of human lifespan could extend to approximately 194 years under optimal conditions, challenging earlier estimates that placed the ceiling around 120 years. While no human has yet come close to this theoretical maximum, the finding has fueled debate about whether aging is a fixed biological limit or a malleable process that can be meaningfully extended.

The Biological Lottery

Not everyone benefits equally from longevity interventions. Research has shown that life-extending treatments can produce dramatically different outcomes depending on genetic background, sex, environmental factors, and baseline health — a phenomenon some scientists have called a “biological lottery.” This variability underscores the importance of personalized medicine approaches in any future anti-aging therapeutic strategy.

Senolytics and Cellular Cleanup

One of the most active areas in longevity research is senolytics — drugs that selectively eliminate senescent cells, the “zombie cells” that accumulate with age and secrete inflammatory molecules that damage surrounding tissue. Dasatinib, identified in the SHARP study as hitting five aging hallmarks, is already being tested in senolytic combinations alongside quercetin in human clinical trials for conditions ranging from osteoarthritis to chronic kidney disease.

What This Means for the Future

The convergence of network medicine, epigenetic biomarkers, and drug repurposing represents a fundamental shift in how we approach the biology of aging. Rather than searching for a single “magic pill,” the field is moving toward a systems-level understanding in which multiple interventions — some pharmacological, some lifestyle-based — are combined to target multiple hallmarks simultaneously.

The 83 network drugs identified in the SHARP study are particularly exciting because they represent a class of compounds that no traditional screening method would have flagged. A nasal decongestant like oxymetazoline, for instance, would never have appeared on a longevity drug candidate list — yet the network analysis revealed that it affects longevity-related genes through indirect protein interactions, and the researchers were able to show mechanistically how this works.

As Albert-László Barabási put it: “As someone whose hair turned gray years ago, I share the universal wish that there might one day be a pill that slows aspects of aging. The challenge is figuring out which drugs are worth testing.”

Thanks to network medicine, that challenge just became significantly more tractable. The next decade will likely see several of these repurposed compounds enter human longevity trials, bringing the dream of extending not just lifespan but healthspan — the period of life spent in good health — closer to reality.

Practical Takeaways While We Wait

While pharmacological interventions are still years away from clinical availability for aging itself, the research reinforces several evidence-based lifestyle strategies that already target the same hallmarks:

• Regular exercise — Physical activity has been shown to reduce cellular senescence, improve mitochondrial function, and enhance intercellular communication, hitting multiple hallmarks simultaneously.
• Caloric restriction and intermittent fasting — These dietary approaches activate cellular repair pathways and have consistently extended lifespan in animal models.
• Quality sleep — Sleep deprivation accelerates telomere shortening and impairs DNA repair mechanisms, both core hallmarks of aging.
• Stress management — Chronic stress elevates inflammation and oxidative stress, accelerating multiple aging processes.
• Social connection — Strong social ties are associated with reduced all-cause mortality, likely through reductions in chronic inflammation and stress hormones.

The science of longevity is no longer fringe. It is a rigorous, data-driven field producing actionable insights at an accelerating pace. The question is no longer whether we can slow aging, but how soon those insights will translate into treatments that reach the clinic — and who will have access to them when they do.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous